EC Dental Science

T cell prolymphocytic leukaemia (T PLL) is an aggressive T cell leukaemia comprised of miniature to intermediate mature T lymphocytes. The leukaemia exhibits elevated quantifiable white blood cells (WBCs) with significant cellular dissemination and incrimination of diverse organs.

Generally, accompanying lymphocytosis exhibits CD4+ and T cell leukaemia/lymphoma protein1 (TCL1) immuno-phenotype. Fluorescent in situ hybridization (FISH) can be beneficially employed to assess genetic rearrangements within T cell leukaemia/lymphoma protein1 (TCL1).

1. Kaseb H., et al. “T Cell Prolymphocytic Leukemia”. Stat Pearls International, Treasure Island, Florida (2022).
2. Mikhaylenko N., et al. “Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia”. PLoS One9 (2022): e0274463.
3. Braun T., et al. “Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways”. Haematologica1 (2022): 187-200.
4. Cross M and Dearden C. “B and T cell prolymphocytic leukaemia”. Best Practice and Research Clinical Haematology 3 (2019): 217-228.
5. Staber PB., et al. “Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia”. Blood14 (2019): 1132-1143.
6. Image 1 Courtesy: ASH.com
7. Image 2 Courtesy: Pathology outlines.